The 2022 Report on Pharmaceutical Preparations Acting on the Human Cardiovascular System: World Market Segmentation by City

The 2022 Report on Pharmaceutical Preparations Acting on the Human Cardiovascular System: World Market Segmentation by City

  • July 2021 •
  • 525 pages •
  • Report ID: 1954716 •
  • Format: PDF
This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries. It does so by reporting the estimated market size (in terms of latent demand) for each major city of the world. It then ranks these cities and reports them in terms of their size as a percent of the country where they are located, their geographic region (e.g. Africa, Asia, Europe, Middle East, North America, Latin America), and the total world market.

This study covers pharmaceutical preparations acting on the human cardiovascular system as defined by the North American Industrial Classification system or NAICS (pronounced "nakes").

The NAICS code for pharmaceutical preparations acting on the human cardiovascular system is 32541271. It is for this definition that aggregate latent demand estimates are derived. Pharmaceutical preparations acting on the human cardiovascular system is specifically defined as follows:

32541271 Pharmaceutical preparations, acting on the cardiovascular system, for human use

3254127100 Pharmaceutical preparations, acting on the cardiovascular system, for human use

3254127111 Anticoagulants

3254127112 ACE inhibitors

3254127113 Other cardiovascular preparations

3254127116 Hemostatics

3254127121 Digitalis preparations

3254127126 Hypotensives, rauwolfia_alkaloid preparations and rauwolfia_diuretic combinations

3254127131 Hypotensives, beta receptor blocking agents

3254127136 Other hypotensives

This study covers the world outlook for pharmaceutical preparations acting on the human cardiovascular system across more than 2,000 cities. For the year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the city in question (in millions of U.S. dollars), the percent share the city is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities of the world). This study gives, however, Professor Parker’s estimates for the worldwide latent demand, or the P.I.E., for pharmaceutical preparations acting on the human cardiovascular system. It also shows how the P.I.E. is divided across the world’s cities. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.